AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03026712 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM tDCS + Robotic Arm Therapy
Description: SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).~The intervention will be performed 5 times per week for 2 consecutive weeks.
Study NCT02958839 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
Study NCT00405665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
Study NCT00405665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Group 2 will receive the inactive treatment followed by the active treatment.
Study NCT05191199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Penile Duplex Study
Description: A penile duplex study will be done to assess PSV, EDV, RI, angle and degree of curvature and Erection quality using the erection hardness grading scale
Study NCT04312152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Q10 Ubiquinol
Description: Q10 Ubiquinol (50 or 100 mg b.i.d. depending on body weight) in capsules containing also Vit. E and Vit. B complex, as described above. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
Study NCT04312152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
Study NCT04312152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E (30 mg b.i.d. regardless of body weight) in capsules containing also Vit. B complex, and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
Study NCT04312152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-Vitamin B complex
Description: Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
Study NCT04312152 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Vitamin B complex
Description: Multi-Vitamin B complex including Vit. B1, B2, B3, B5, B6, B8, B9, and B12, in capsules containing also Vit. E and, in the active arms, Q10 ubiquinol. Capsules can be opened and the content drunk or chewed, if children have difficulties with swallowing capsules.
Study NCT01710839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5mg Ranibizumab
Description: intravitreal injections
Study NCT01710839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5mg Ranibizumab
Description: intravitreal injections
Study NCT01710839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Pan Retinal Photocoagulation
Description: Targeted Pan Retinal Photocoagulation based on wide field angiography
Study NCT02821975 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive computer training
Description: COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
Study NCT01641731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cow's milk
Description: Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.~Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached.
Study NCT02707562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 1
Description: two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
Study NCT02707562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 2
Description: two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
Study NCT02707562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1837 dose 3
Description: two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
Study NCT02658253 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alhydrogel
Description: 0.85 mg og Aluminium content
Study NCT02658253 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Na cl
Study NCT02548143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor VIIa (Recombinant)
Description: LR769
Study NCT05244694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Priming dose then a constant infusion at 40 mU•m-2•min-1
Study NCT01134250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2 in combination with paclitaxel
Description: Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent.
Study NCT03856411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
Study NCT03856411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION (JS001 ) combine with chemotherapy
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo ,240mg/6ml/vial, Q3W,up to 2 years of treatment.
Study NCT02015728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor biology testing
Description: Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the best available combination of low-dose oral cytotoxic agents, including temozolomide and etoposide.
Study NCT03804853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitiation
Description: This study will be a non-blinded randomized controlled outcomes study evaluating outcomes at baseline, 2 weeks, 6 weeks, 3 months, 6 months, and 1 year post-operatively from a primary reverse total shoulder arthroplasty with two different post-operative physical rehabilitation protocols. There will be 2 groups, one undergoing the immediate active shoulder physical therapy protocol consisting of four quadrant stretches and full active motion of the shoulder from post op day 1 in the hospital. The second group will follow the traditional TRIA physical therapy protocol consisting of PT (standard of care) followed by a gradual return to active range of motion of the shoulder beginning by week 6, calling for 18 physical therapy visits. The physical therapy will occur where the patient is most comfortable receiving it.
Study NCT01910415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor
Study NCT01910415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumacaftor Placebo
Study NCT01910415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor
Study NCT01910415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor Placebo
Study NCT01910415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxifloxacin hydrochloride
Study NCT04400565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery group
Description: The researchers designed a recovery group suited to Taiwanese with mental illness, according to content of the Pathways to Recovery (PTR): A Strengths Recovery Self-Help Workbook (Ridgway et al., 2002) and recovery-related literature (Davidson et al., 2005; Ridgway, 2001)
Study NCT03538366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor FMT
Description: Fecal transplant from unrelated, healthy donors using enemas
Study NCT02399774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leboride
Description: 1. Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups~   1. Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.~  2. Control group: participants will not receive any device for breastfeeding pain control~2. Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device.
Study NCT04706481 — intervention group
Intervention type: PROCEDURE
Intervention: Specimen Collection
Description: Specimens obtained from surgical, phlebotomy or other non-invasive procedure
Study NCT02378324 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Screening without fee
Description: All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
Study NCT02309008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028
Description: Participants will receive PAC-14028 cream applied topically once a day for 9 days
Study NCT02309008 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Participants will receive vehicle cream applied topically once a day for 9 days
Study NCT03257033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy
Study NCT03257033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Chemotherapy
Study NCT03257033 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: Chemotherapy
Study NCT03257033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RenovoCath
Description: Intra-arterial catheter
Study NCT02602522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shandong Danshen-Jiang-Fu Granule
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
Study NCT02602522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shandong Danshen-Jiang-Fu Granule
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
Study NCT02602522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sichuan Danshen-Jiang-Fu Granule
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
Study NCT02602522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sichuan Danshen-Jiang-Fu Granule
Description: Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
Study NCT02150278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention
Description: The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
Study NCT02212041 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: disposable electronic cigarettes
Description: Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.~During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained.
Study NCT00849368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine / Allopurinol
Description: Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.~Azathioprine: Imurek (R) 50 mg and 25 mg tablets~Allopurinol: Mephanol (R) 100 mg tablets
Study NCT01914666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally
Study NCT03271879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin at a dose of 10 mg/day
Description: Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
Study NCT03271879 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin at a dose of 10 mg/day
Description: Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
Study NCT00966706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given systemically
Study NCT00966706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Description: Given systemically
Study NCT03251573 — intervention group
Intervention type: OTHER
Intervention: cognitive impairment
Description: one are of patients were exposed to cognitive impairment
Study NCT03765736 — intervention group
Intervention type: OTHER
Intervention: Genetic Testing
Description: Undergo genetic testing
Study NCT00423306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darinaparsin
Description: 420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
Study NCT03921710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPA-IVM
Description: Immature oocytes were plated into a 4-well dish (Nunc, Denmark) at 10 COCs/well using CAPA medium (Medicult IVM medium; Origio, Denmark supplemented with 1 mIU/mL rFSH, 5 ng/mL insulin, 10 nM estradiol, 10 mg/mL human serum albumin \[SAGE, Denmark\] and 25 nM CNP under oil for 24 h at 37°C, 6% carbon dioxide in air). After 24 hours, COCs were washed and transferred into IVM medium (Origio, Denmark) containing 5 ng/mL insulin, 10 nM estradiol, 100 ng/mL human recombinant amphiregulin and 100 mIU/mL rFSH, and incubated under oil for 30 h at 37°C, 6% carbon dioxide in air.
Study NCT03921710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-IVM
Description: Immature oocytes are plated into a 4-well dish at 10 COCs/well using IVM medium supplemented with 75 mIU/mL recombinant FSH (Merck, Switzerland), 100 mIU/mL hCG (MSD, USA), 0.01 mg/mL growth hormone (Merck, Switzerland) and 10 mg/mL human serum albumin (SAGE, Denmark). COCs were incubated for 30 hours at 37°C, 6% carbon dioxide in air.
Study NCT03561857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal Laser Endomicroscopy
Description: The study is divided in 2 parts.~1. Ex vivo study~   * Prostate specimens will be stained using Fluorescein~  * Images/sequences of normal and abnormal prostatic tissues, and peri-prostatic tissues will be acquired.~2. In vivo study~   * Intravenous injection of contrast agent~  * pCLE imaging every 5mm of the NVB dissection zone.
Study NCT00353743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00353743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline plus metronidazole
Description: doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
Study NCT00393679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amodiaquine-artesunate (ASAQ)
Description: A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
Study NCT00393679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine (DHAPQ)
Description: DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
Study NCT00393679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine (AL)
Description: Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
Study NCT00393679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)
Description: Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.~TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008.
Study NCT03592615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cataract surgery
Description: Cataract surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than cataract, e.g., treatment for lens dislocation. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating astigmatism.
Study NCT03592615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal refractive surgery
Description: Corneal refractive surgery in this study is only for the purpose of vision correction, not for the treatment of ocular pathology other than refractive error, e.g., treatment for corneal scar. The surgery used in this study should not be combined with other procedures, such as limbal relaxing incision for treating severe astigmatism.
Study NCT02015728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors.
Study NCT00966706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given systemically
Study NCT00874393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dopamine
Description: Dopamine
Study NCT00874393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Hydrocortisone
Study NCT00874393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Infusion Placebo
Description: Dextrose (D5W)